Moors & Cabot, Inc.
- SEC CIK
- 0001607239
- Latest filing
- Aug 10, 2026
LCTX holding history
Lineage Cell Therapeutics, Inc. in every 13F filed by Moors & Cabot, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LCTX overviewAll 13F holders of LCTXFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −12,400−100.0% | Sold out | Holders |
| Q1 2023 | 12,400 | $18.6K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 12,400 | $14.5K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 12,400 | $14.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 12,400 | $20.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2022 | 12,400 | $19.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2021 | 12,400 | $30.0K | <0.1% | −6,000−32.6% | Reduced | Holders |
| Q3 2021 | 18,400 | $47.0K | <0.1% | −4,960−21.2% | Reduced | Holders |
| Q2 2021 | 23,360 | $67.0K | <0.1% | +3,690+18.8% | Added | Holders |
| Q1 2021 | 19,670 | $46.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.